BioLargo Equipment Solutions & Technologies, Inc., a subsidiary of BioLargo, Inc., has announced a strategic partnership with Aquatech aimed at accelerating the commercialization of its Aqueous Electrostatic Concentrator (AEC) technology. This venture seeks to enhance the treatment of per- and polyfluoroalkyl substances (PFAS), which are increasingly scrutinized due to their environmental and health implications.
The AEC is designed specifically to remove PFAS from liquid streams, generating water that meets drinking quality standards. The technology utilizes an electromotive process that collects PFAS compounds onto membrane surfaces, effectively eliminating secondary waste disposal concerns.
Under the memorandum of understanding (MOU), BioLargo and Aquatech will work together to incorporate the AEC as a pivotal component in Aquatech’s comprehensive PFAS treatment solutions. This partnership is expected to enhance the capabilities offered to public and private sectors striving to comply with evolving regulatory mandates.
Aquatech is renowned for its advanced solutions in water and wastewater management, having received accolades such as Water Technology Company of the Year at the 2025 Global Water Summit. The company brings a robust portfolio of technologies, including electrochemical and biological treatment systems.
The agreement establishes a globally applicable framework for collaborative projects, allowing both entities to leverage their respective strengths in addressing PFAS contamination. This alliance is a strategic move for BioLargo, reinforcing its initiative to expand market reach through partnerships with industry leaders.
The MOU signifies a strategic partnership aimed at accelerating the commercialization of BioLargo's Aqueous Electrostatic Concentrator (AEC) technology for PFAS treatment. Leveraging Aquatech's expertise enhances market opportunities and the potential for scalable solutions in a rapidly growing sector.
BioLargo's AEC employs electromotive force to effectively remove PFAS substances from liquid streams, creating treated water suitable for drinking. This innovative approach eliminates the production of secondary waste streams, positioning it as a more sustainable solution in water treatment.
PFAS, or per- and polyfluoroalkyl substances, are a group of harmful chemicals often found in water sources. The removal of PFAS is essential to meet regulatory standards and address public health concerns, making technologies like BioLargo's AEC increasingly relevant.
Collaborating with Aquatech, a leader in water and wastewater management, provides BioLargo with access to advanced resources and a broader market. This partnership enhances their capability to deliver comprehensive PFAS treatment solutions, potentially accelerating revenue growth.
The partnership aims to streamline the PFAS treatment process, enabling clients in municipal and industrial sectors to better meet evolving regulatory requirements, thereby reducing compliance risks and enhancing operational efficiency.
The collaboration is anticipated to fast-track the development and deployment of effective PFAS treatment solutions, responding to the increasing demand for remediation technologies and possibly leading to significant market share expansion for both companies.
The partnership with Aquatech positions BioLargo to capitalise on a growing market for PFAS treatment technologies. By integrating their innovative solutions, BioLargo may enhance its competitive advantage and revenue potential in the environmental technology sector.
BioLargo's focus on developing sustainable technologies, such as the AEC for PFAS treatment, reflects a commitment to addressing critical environmental challenges. This strategy not only aligns with global sustainability goals but also enhances their appeal to environmentally conscious investors.